TICKERNERD
Menu
SHPHSHPHHealthcare · Drug Manufacturers - Specialty & Generic

SHPH Stock Forecast: Shuttle Pharmaceuticals Holdings, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$3.53
0.00% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 12 Sept 2026 — in the weakest quartile.

Market cap
$2.1M
Ticker Nerd rank
16 / 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$2.2M
Net income−$2.2M
Free cash flow−$2.5M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.4%
1M
−18.1%
YTD
−80.4%
1Y
−89.9%
From 52W high
−92.6%
From 52W low
+27.0%
$3
$48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SHPH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Shuttle Pharmaceuticals Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
16 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
99
Growth
62
Issuance
48
Accruals
30
Momentum
25
Revisions
25
Volatility
20
Quality
7
Value
1

Size (99): Smaller than most of the companies we track.

Value (1): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SHPH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SHPH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26SHPH

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SHPH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SHPH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Shuttle Pharmaceuticals Holdings, Inc. returned −89.9% against +17.5% for the S&P 500, dividends included.

SHPH vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Oct 25Jan 26Apr 26Jul 26SHPHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SHPH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
35.3×

Cheaper than 21% of US stocks

Price / sales
—
Price / book
0.6×

Cheaper than 83% of US stocks

EV / EBITDA
−0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−326.4%

Higher than 5% of US stocks

Return on assets
−81.7%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Shuttle Pharmaceuticals Holdings, Inc. has a market value of $2.1M and an enterprise value of $1.2M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$10.8M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$12.5M.

  • Shuttle Pharmaceuticals Holdings, Inc. spent $0.0 on dividends in the twelve months to 31 Mar 2026.

  • Shares outstanding: 555,129.

  • Trailing P/E: 35.3×.

  • Shuttle Pharmaceuticals Holdings, Inc. employs 2 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

SHPH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
SHPHShuttle Pharmaceuticals Holdings, Inc.$2.1M
16
BTAIBioXcel Therapeutics, Inc.$2.3M
—
PRFXPRF Technologies Ltd.$2.6M
4
APUSApimeds Pharmaceuticals US, Inc.$3.2M
9
SXTCChina Sxt Pharmaceuticals, Inc.$3.4M
11
SBFMSunshine Biopharma, Inc.$4.1M
61
IMCCIM Cannabis Corp.$1.1M
29

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Shuttle Pharmaceuticals Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SHPH news & analysis

Shuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance Letter

Newsfile Corp · 28 Aug 2026negative

Shuttle Pharmaceuticals announced it received a NASDAQ noncompliance letter for failing to file its Form 10-Q for the fiscal quarter ended June 30, 2026 by the required due date, in violation of Nasdaq Listing Rule 5250(c)(1). The company stated it intends to file the report as soon as practicable.

Why it matters — Failure to meet Nasdaq's periodic filing requirements could jeopardize the company's continued listing status on the exchange, which is a key concern for SHPH shareholders.

FAQ

Frequently asked questions about SHPH stock

How does Ticker Nerd's model rank SHPH?

As at 12 Sept 2026, Shuttle Pharmaceuticals Holdings, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

What is the SHPH stock forecast for 2030?

No analyst covering Shuttle Pharmaceuticals Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SHPH are extrapolating price history, which says nothing about the business.

How has SHPH stock performed over the past year?

Shuttle Pharmaceuticals Holdings, Inc. returned -89.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Shuttle Pharmaceuticals Holdings, Inc. do?

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing cancer therapies, with a particular emphasis on improving the effectiveness of radiation treatment.

What is the latest news on SHPH?

The most recent item we track (Newsfile Corp, 28 Aug 2026): "Shuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance Letter". Shuttle Pharmaceuticals announced it received a NASDAQ noncompliance letter for failing to file its Form 10-Q for the fiscal quarter ended June 30, 2026 by the required due date, in violation of Nasdaq Listing Rule 5250(c)(1). The company stated it intends to file the report as soon as practicable.

Company

About Shuttle Pharmaceuticals Holdings, Inc.

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing cancer therapies, with a particular emphasis on improving the effectiveness of radiation treatment. Its current work centers on radiation sensitizers and related oncology programs designed to support treatment outcomes across difficult-to-treat cancers. The company also owns an AI-driven molecular discovery platform, Molecule.ai, which is used for early-stage drug development and helps researchers explore and evaluate new chemical ideas more efficiently. In addition to its therapeutic pipeline, Shuttle Pharmaceuticals Holdings, Inc. is involved in cancer-focused diagnostics and drug-development technologies that connect oncology research with precision medicine workflows. Headquartered in Gaithersburg, Maryland, the company operates as a small, research-driven healthcare business positioned within the broader pharmaceutical and biotechnology market.

CEO Mr. Christopher Robert Cooper BBA, M.B.A. · 2 employees · United States · https://www.shuttlepharma.com